Notice of Interim Results

Oxford, UK – 15 July 2016: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty biopharmaceutical company focused on allergy and respiratory medicine, will announce its interim results for the six months ended 30 June 2016 on Tuesday 27 September 2016. At the same time, the Company will provide a strategy update. This will include its progress in establishing the Company’s commercial infrastructure as a strategic growth platform and advances in its wider portfolio of specialty products.

Following the 20 June announcement of top-line results from its cat allergy phase III study, Circassia has now stopped development activities in its grass and ragweed allergy programmes. The phase IIb study of its house dust mite allergy treatment is already well advanced and will continue to completion in Spring next year. The Company’s birch allergy product is nearing completion of a phase II study, which will therefore also continue.

Circassia is currently undertaking a detailed review of the cat allergy phase III data it has received to date and is consulting external experts. On receipt of the complete dataset, which is expected at the end of July, Circassia will undertake a full analysis and work with external experts to understand whether any confounding factors affected the results as well as the implications for its wider allergy portfolio. Circassia anticipates announcing the outcome of this process at its interim results, or beforehand if possible.

Following the announcement of its interim results on 27 September, the Company will hold an analyst meeting at 9.30am at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. A webcast of the event will be available in the Media section of the Company’s website at www.circassia.com.

For further information please contact:

FTI Consulting
Mo Noonan
+44 (0) 20 3727 1390